For the Inventor, By the Inventor

Enter assignee name

Vienna, Austria

Baxter Aktiengesellschaft

USPTO Granted Patents = 67

% Expired Patents = 9.0

CIPO Patents = 4

EPO Patents = 4

Trademarks = 1

Forward Citations = 1,174

Loading Chart...

Loading Chart...

85 inventors (with patents filed for the assignee):

Johann J Eibl (29 out of 102 patents)

Friedrich Dorner (28 out of 91 patents)

Hans-Peter Schwarz (14 out of 107 patents)

4. Peter Turecek (14 out of 120 patents)

5. Bernhard Fischer (10 out of 62 patents)

6. Artur Mitterer (9 out of 53 patents)

7. Uwe Schlokat (9 out of 13 patents)

8. Heinz Redl (7 out of 27 patents)

9. Falko-Guenter Falkner (6 out of 17 patents)

10. Guenther Schlag (6 out of 6 patents)

11. Noel Barrett (5 out of 19 patents)

12. Michele Himmelspach (5 out of 7 patents)

13. Michael Pfleiderer (5 out of 6 patents)

14. Friedrich Scheiflinger (4 out of 76 patents)

15. Wolfgang Mundt (4 out of 63 patents)

Core Competencies:

Fibrinogen

Factor VIII

Blood Coagulation

Pathogen Detection

Vaccine Composition

Recombinant Proteins

Immunotolerant Complex

Furin Polypeptides

Thrombolytic Substances

Nucleic Acids

Hybrid Proteins

Biological Samples

67 patents: Sort by Forward Citations

1. 8709492 - Process for producing a plasma protein-containing medicament with reduced concentration of citrate and metals (2014-04-29),

2. 8425947 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2013-04-23),

3. 7892802 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2011-02-22),

4. 7459295 - Fibrinogen-based tissue adhesive containing an elastase inhibitor (2008-12-02),

5. 7279161 - Factor IX/factor IXa activating antibodies and antibody derivatives (2007-10-09),

6. 7241603 - Method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method (2007-07-10),

7. 7220569 - Nucleic acids encoding factor X analogues having a modified protease cleavage site (2007-05-22),

8. 7094574 - Recombinant cell clones having increased stability and methods of making and using the same (2006-08-22),

9. 7091325 - Fibrin/fibrinogen-binding conjugate (2006-08-15),

10. 7091015 - Fibrinogen-based tissue adhesive (2006-08-15),

11. 7033590 - Factor IX/factor IXa activating antibodies and antibody derivatives (2006-04-25),

12. 7005502 - Pharmaceutical preparation comprising vWF propeptide (2006-02-28),

13. 6974792 - Alpha 1-antitrypsin preparation as well as a method for producing the same (2005-12-13),

14. 6958322 - Factor X analog with an improved ability to be activated (2005-10-25),

15. 6953837 - Factor VIII/vWF complexes and compositions (2005-10-11),

Company Overview

Baxter Aktiengesellschaft, headquartered in Vienna, Austria, specializes in the development and manufacturing of innovative solutions in blood coagulation. The company focuses on critical areas such as fibrinogen and Factor VIII, which are essential for effective blood clotting. Additionally, Baxter is engaged in advanced research on pathogen detection, vaccine composition, and recombinant proteins, contributing to the field of immunotolerant complexes and furin polypeptides. Their work aims to enhance patient outcomes in hematology and related medical fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

67 Patents

#13 in Vienna

#61 in Austria

#11,031 in the World

Vienna, Austria

Baxter Aktiengesellschaft

Forward Citations = 1,174

85 inventors:

Johann J Eibl (29 out of 102 patents)

Friedrich Dorner (28 out of 91 patents)

Hans-Peter Schwarz (14 out of 107 patents)

4. Peter Turecek (14 out of 120 patents)

5. Bernhard Fischer (10 out of 62 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Baxter Aktiengesellschaft. Retrieved from https://idiyas.com/company/baxter-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…